

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A - Pipeline Review, H2 2019

<https://marketpublishers.com/r/CC01F95A7900EN.html>

Date: December 2019

Pages: 34

Price: US\$ 3,500.00 (Single User License)

ID: CC01F95A7900EN

Abstracts

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A - Pipeline Review, H2 2019

SUMMARY

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A - Pipeline Review, H2 2019, outlays comprehensive information on the cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A is an enzyme which plays a critical role in regulating cAMP and cGMP levels in the striatum. Many cellular responses are regulated by second messengers like cAMP and cGMP. PDE10A eliminate cAMP- and cGMP-mediated intracellular signaling by hydrolyzing the cyclic nucleotide to the corresponding nucleoside 5-prime monophosphate. The molecules developed by companies in Phase I and Preclinical stages are 1 and 7 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous

System, Oncology and Genetic Disorders which include indications Schizophrenia, Huntington Disease, Lung Cancer, Cognitive Disorders, Epilepsy, Fragile X Syndrome, Psychiatric Disorders and Psychosis.

Furthermore, this report also reviews key players involved in cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE

The report provides a snapshot of the global therapeutic landscape for cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35)

The report reviews cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) targeted therapeutics and enlists all their major and minor projects

The report assesses cAMP and cAMP Inhibited cGMP 3',5' Cyclic

Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A

(Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Overview

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A

(Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A

(Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A

(Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Companies Involved in Therapeutics Development

AbbVie Inc

ADT Pharmaceuticals Inc

Celon Pharma SA

Merck & Co Inc

Sunovion Pharmaceuticals Inc

Takeda Pharmaceutical Co Ltd

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A

(Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Drug Profiles

ADT-048 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

balipodect - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPL-50003602 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MCI-020 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PyP-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RO-5461861 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SEP-39 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PDE10A for Schizophrenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

THPP-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A

(Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Dormant Products

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A

(Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by AbbVie Inc, H2 2019

Pipeline by ADT Pharmaceuticals Inc, H2 2019

Pipeline by Celon Pharma SA, H2 2019

Pipeline by Merck & Co Inc, H2 2019

Pipeline by Sunovion Pharmaceuticals Inc, H2 2019

Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019

Dormant Projects, H2 2019

Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

COMPANIES MENTIONED

AbbVie Inc

ADT Pharmaceuticals Inc

Celon Pharma SA

Merck & Co Inc

Sunovion Pharmaceuticals Inc

Takeda Pharmaceutical Co Ltd

I would like to order

Product name: cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/CC01F95A7900EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CC01F95A7900EN.html>